Immune checkpoint inhibitors have shown promising therapeutic outcomes in many types of cancer, but ovarian cancer has been an exception.

April 15th saw the Food and Drug Administration (FDA) approval of mitomycin gel (Jelmyto) for the treatment of low-grade upper tract urothelial cancer.

The early detection of cancer improves outcomes for patients – in terms of both reducing treatment burden and improving the chances of a cure.

The spread of novel betacoronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly escalated to a pandemic unseen for generations.